Patrys granted U.S patent for lead human anti-body product

Patrys announced today that it has received a U.S patent for its lead product PATPM1, a promising new human antibody shown to be effective in the treatment of solid tumors and metastases across a number of indicators including pancreatic, lung, breast, colon and gastric cancers.

Patrys said that the U.S patent represents a significant milestone for the company, paving the way for the products’ acceptance in other key markets while also opening the door for its full portfolio of human anti-body treatments.

“The issuance of a U.S patent is further validation of the novelty of our products and reinforces the therapeutic promise our products offer to cancer patients where existing treatments have failed,” said Patrys CEO Daniel Devine.

Extending to 2023, he added that the patent represents a significant commercial opportunity for the company given the dearth of novel cancer treatments currently available in the U.S. It also augurs well for the success of other Patrys patent applications, notably for its PAT-LM1 and PAT-SM6 antibody products, which are similar in breadth and scope. Patrys currently has patent applications for these and other products in Europe and other key markets.

Patrys shares were up 25 percent to $0.125 by mid-afternoon.